REVLIMID® (lenalidomide) in combination with dexamethasone (dex) is indicated for the treatment of adult patients with multiple myeloma (MM). REVLIMID is indicated as maintenance therapy in adult patients with MM following autologous hematopoietic stem cell transplantation (auto-HSCT). REVLIMID is not indicated and is not recommended for the treatment of patients with chronic lymphocytic leukemia (CLL) outside of controlled clinical trials.

Resources for patients and caregivers.

Share these helpful tools and resources with patients with multiple myeloma and their caregivers.

Treatment Overview

A brochure for patients with multiple myeloma who have been prescribed REVLIMID.

Maintenance Brochure

An informative brochure for patients on REVLIMID Maintenance therapy.

Caregiver Brochure

Caregivers can get information and resources to help them care for patients with multiple myeloma.

Full Prescribing Information

Explore the full Prescribing Information, including Boxed WARNINGS.

Medication Guide

Read the Medication Guide and help patients understand the potential side effects associated with REVLIMID treatment.


Additional resources.

Patient Brochure

A resource for your African American patients living with MM. Download the Standing in the Gaap patient brochure to learn more. These patients can also join the Standing in the Gaap community on Facebook.

Myeloma Central

A website for patients living with MM, offering a Welcome Kit containing treatment calendars, lab test trackers, support, and more.


My Moments, My Support

Encourage patients to sign up for My Moments, My Support to receive a patient starter kit and ongoing education and support.


  • MM, multiple myeloma.

Learn more about the Lenalidomide REMS program.

Find Out Now